C07K 2317/73
Inducing cell death
Official title: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K2317/73 (Inducing cell death) appears on 7,733 US grants and 14,697 published applications in this corpus.
Search patents in C07K- Granted patents
- 7,733
- Published applications
- 14,697
- Assignees
- 3,333
- Inventors
- 19,519
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 4 | 0 |
| 1989 | 2 | 0 |
| 1990 | 8 | 0 |
| 1991 | 4 | 0 |
| 1992 | 5 | 0 |
| 1993 | 3 | 0 |
| 1994 | 6 | 0 |
| 1995 | 11 | 0 |
| 1996 | 25 | 0 |
| 1997 | 54 | 0 |
| 1998 | 59 | 0 |
| 1999 | 61 | 0 |
| 2000 | 50 | 0 |
| 2001 | 45 | 13 |
| 2002 | 57 | 110 |
| 2003 | 43 | 154 |
| 2004 | 47 | 169 |
| 2005 | 40 | 252 |
| 2006 | 59 | 253 |
| 2007 | 61 | 293 |
| 2008 | 123 | 309 |
| 2009 | 157 | 420 |
| 2010 | 213 | 442 |
| 2011 | 231 | 493 |
| 2012 | 264 | 441 |
| 2013 | 312 | 515 |
| 2014 | 300 | 573 |
| 2015 | 364 | 551 |
| 2016 | 400 | 705 |
| 2017 | 433 | 724 |
| 2018 | 407 | 742 |
| 2019 | 456 | 796 |
| 2020 | 522 | 886 |
| 2021 | 494 | 937 |
| 2022 | 508 | 1021 |
| 2023 | 486 | 981 |
| 2024 | 534 | 1219 |
| 2025 | 554 | 1047 |
| 2026 | 327 | 651 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Means for specifically eliminating perilipin-1 fragment presenting adipocytes29 Sep 2026US 12,747,286 B2Alytas Therapeutics GmbH
- Multispecific antibodies targeting cd3 and cd228 Oct 2026US 2026/0308255 A1
- Il-5raxcd3e t cell engaging bispecific antibody and uses thereof8 Oct 2026US 2026/0308264 A1Ajou University Industry-Academic Cooperation Foundation
- Novel Use of Anti-BLyS Antibodies8 Oct 2026US 2026/0308266 A1GlaxoSmithKline Intellectual Property Limited
- Anti-nme antibody and method of treating cancer or cancer metastasis8 Oct 2026US 2026/0308282 A1Minerva Biotechnologies Corporation
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998